🔗 Share this article

As the US proceeds with sweeping changes to its vaccination schedules, a particular individual has surfaced somewhat surprisingly: Høeg, a Danish American sports medicine doctor and public health researcher who first made her name by casting doubt on Covid vaccinations in the global health crisis and has focused upon alleged deaths after Covid immunization in her recent tenure at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Childhood Vaccine Schedule

Public health authorities planned to reveal major revisions to the pediatric vaccine schedule in December, synchronizing the US with Denmark’s national calendar, it is understood – a major change that would place the US at odds with much of the global community with little proof for public health gain. The announcement has been pushed back until the coming year.

Instead of Vinay Prasad, Høeg is set to address the audience at the meeting. She was just designated interim head of the FDA’s drug evaluation center, the fifth person to run the center this year.

Consolidating Power at the FDA

Høeg's temporary position might represent a closer partnership between the drug and biologics branches as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it suggests a greater focus upon rolling back already-approved immunizations at the FDA.

The new acting director has repeatedly called for discontinuing certain pediatric immunization guidelines in the US so as to align more similar to Denmark, a country with universal health coverage and a population about the size of Wisconsin’s.

So far public appearances, she has continued to focus on vaccination policy – usually the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Questions Over Qualifications

The appointee has no apparent background in drug development, regulation or leadership, which has been customary for previous heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the commissioner and the vaccine center since March.

“She appears not to have the necessary background” for overseeing the CDER, remarked Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She has no expertise in leading a large organization. She has no expertise in drug approvals.”

Previous directors of CBER would “understand regulatory frameworks and the underlying principles of pharmaceutical innovation”, said Dr. Janet Woodcock. “Clearly, she lacks the type of experience that former directors who ran CBER have had.”

The drug center has an vast range of responsibilities at the agency, she stated.

“The public just focuses on the novel medication approvals, but the generic drug division authorizes numerous generic drugs. There is also a biosimilars program, OTC medication office and so forth, and each of these need to be looked after,” Dr. Woodcock said. “The area you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

There is also, a substantial leadership component to the job, which manages over 5,000 staff members. “It is a huge leadership role, if you perform it correctly,” the former official said.

Official Statement and Contentious Policies

Regarding questions about Dr. Høeg's fitness for the role and whether this assignment indicates increased cooperation among agency officials on vaccines, a spokesperson stated that the “inquiries are based on incorrect premises”.

“Her experience matches the responsibilities of her role,” the official explained, citing the time Høeg spent guiding the agency head on “drug safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s controversial priority voucher program, a controversial expedited drug-approval program that reportedly troubled her predecessors. “By what process are these drugs being chosen for this expedited pathway? Who takes the choices?” Dr. Howard asked. “There’s a lot of lack of transparency happening at the regulatory body right now.”

In general, he said, “the FDA seems to be moving towards laxer oversight of pharmaceuticals, except for vaccines.”

Documented Track Record on Vaccines

Regarding vaccines, Dr. Høeg has a more documented, if problematic, past, some experts have noted. She released a analysis using unconfirmed crowd-sourced reports to assess the incidence of myocarditis after Covid vaccination. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who reportedly have modified findings to imply COVID-19 vaccinations are riskier than they are.

Included in her “wish list” for the current federal leadership featured changing regulations for recently developed shots and ending “non-essential” immunizations, she stated post-election on a podcast. At the FDA, Dr. Høeg has according to sources suggested barring young men from receiving Covid vaccinations.

“She’s an complete true believer who commences with her preconceived notions and works backwards to fit the science in a highly disingenuous, dishonest way,” Howard stated.

Gaining Influence and a “Revenge Tour”

Dr. Høeg became part of fellow dissenters, {like|